Cargando…

Retrospective Cohort Study Comparing Infliximab-dyyb and Infliximab in Biologic-Naive Patients With Inflammatory Bowel Disease in the United States

BACKGROUND: Real-world assessments of biosimilars are needed to understand their effectiveness and safety in practice settings that may differ from those seen in clinical trials or healthcare systems in different countries. To assess the effectiveness and safety of a biosimilar (infliximab-dyyb) and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smith, Joshua T, Velayos, Fernando S, Niu, Fang, Liu, Vincent, Delate, Thomas, Pola, Suresh, Le, Kim, Hui, Rita L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Observations and Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802363/ https://www.ncbi.nlm.nih.gov/pubmed/36776661 http://dx.doi.org/10.1093/crocol/otab051

Ejemplares similares

Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study
por: Ho, Stephanie L., et al.
Publicado: (2020)

Correction to: Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study
por: Ho, Stephanie L., et al.
Publicado: (2020)

Patient Perspectives on Switching from Infliximab to Infliximab‐dyyb in Patients with Rheumatologic Diseases in the United States
por: Chau, Jason, et al.
Publicado: (2019)

Process and Clinical Outcomes of a Biosimilar Adoption Program with Infliximab-Dyyb
por: Bhat, Shubha, et al.
Publicado: (2020)

Identifying biosimilar side effects: Infliximab-dyyb-associated subcorneal pustular dermatosis
por: Gozo, Maria Amoreth R., et al.
Publicado: (2020)

Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease
por: Guerra Veloz, María Fernanda, et al.
Publicado: (2018)

Real-world data on the infliximab biosimilar CT-P13 (Remsima(®)) in inflammatory bowel disease
por: Huguet, Jose María, et al.
Publicado: (2021)

Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study)
por: Abraham, Bincy, et al.
Publicado: (2022)

Ideal Vial Size for Infliximab in the Treatment of Inflammatory Bowel Disease: An Analysis of Pharmaceutical Waste and Physician Opinions
por: Schachne, Jonathan M, et al.
Publicado: (2021)

Infliximab in inflammatory bowel disease
por: Papamichael, Konstantinos, et al.
Publicado: (2019)

Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases: A multicenter study
por: Viola, Anna, et al.
Publicado: (2017)

Management of inflammatory bowel disease in poor responders to infliximab
por: Guerra, Iván, et al.
Publicado: (2014)

Switching From Reference Infliximab to Biosimilar CT-P13 Did Not Change Quality of Life in Stable Inflammatory Bowel Disease Patients
por: Pierik, Marieke J, et al.
Publicado: (2021)

Inflammatory bowel disease of the lung: The role of infliximab?()
por: Hayek, Adam J., et al.
Publicado: (2015)

Efficacy of Infliximab Biosimilar for Maintenance Therapy in Pediatric Inflammatory Bowel Disease Following Infliximab Originator
por: Hinshaw, Amie, et al.
Publicado: (2022)

Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis
por: Sablich, Renato, et al.
Publicado: (2023)

Accelerated Infliximab Infusion Safety and Tolerability Is Non-inferior to Standard Infusion Protocol in Inflammatory Bowel Disease Patients: A Randomized Controlled Study
por: Abushamma, Suha, et al.
Publicado: (2023)

Infliximab in the Treatment of Crohn Disease and Type 1 Diabetes
por: Timper, Katharina, et al.
Publicado: (2013)

Elevated Pretreatment Plasma Oncostatin M Is Associated With Poor Biochemical Response to Infliximab
por: Minar, Phillip, et al.
Publicado: (2019)

Real-World Experience With Proactive Therapeutic Drug Monitoring During Infliximab Reintroduction
por: Normatov, Inessa, et al.
Publicado: (2021)

Cost-effectiveness Analysis of Subcutaneous Infliximab for Inflammatory Bowel Diseases in Sequential Biologic Treatment
por: Bouhnik, Yoram, et al.
Publicado: (2022)

Declining use of combination infliximab and immunomodulator for inflammatory bowel disease in the community setting
por: Berkowitz, Joshua C, et al.
Publicado: (2018)

Clinical role, optimal timing and frequency of serum infliximab and anti-infliximab antibody level measurements in patients with inflammatory bowel disease
por: Bor, Renáta, et al.
Publicado: (2017)

A descriptive analysis of real-world treatment patterns of innovator (Remicade(®)) and biosimilar infliximab in an infliximab-naïve Turkish population
por: Yazici, Yusuf, et al.
Publicado: (2018)

Does infliximab increase complications after surgery for inflammatory bowel disease?
por: Holubar, Stefan D, et al.
Publicado: (2009)

Infliximab-Associated Acneiform Eruption in a Patient With Inflammatory Bowel Disease
por: Khatana, Usman Feroze, et al.
Publicado: (2021)

Pharmacogenetic variants of infliximab response in young patients with inflammatory bowel disease
por: Curci, Debora, et al.
Publicado: (2021)

Outcome of Immediate Dose Optimization of Infliximab in Inflammatory Bowel Disease Patients
por: Bacsur, Péter, et al.
Publicado: (2021)

Adherence patterns in naïve and prevalent use of infliximab and its biosimilar
por: Alanaeme, Chibuike J., et al.
Publicado: (2022)

Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn’s disease in China
por: Shi, Ji-Hao, et al.
Publicado: (2020)

Mo1055: COST-EFFECTIVENESS ANALYSIS OF SUBCUTANEOUS INFLIXIMAB FOR INFLAMMATORY BOWEL DISEASES IN SEQUENCIAL BIOLOGICAL TREATMENT
por: Baik, Deborah, et al.
Publicado: (2022)

A Mobile Infliximab Dosing Calculator for Therapy Optimization in Inflammatory Bowel Disease
por: Piester, Travis, et al.
Publicado: (2018)

Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective
por: Milassin, Ágnes, et al.
Publicado: (2019)

Tenascin-C Is Increased in Inflammatory Bowel Disease and Is Associated with response to Infliximab Therapy
por: Ning, Longui, et al.
Publicado: (2019)

Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease
por: Grišić, Ana‐Marija, et al.
Publicado: (2021)

Predictive factors of response to infliximab therapy in Brazilian inflammatory bowel disease patients
por: Martins, Camilla de Almeida, et al.
Publicado: (2023)

Comparison of 3 Enzyme-Linked Immunoassay Methods to Evaluate Serum Concentrations of Infliximab and Antibodies to Infliximab in 32 Patients with Moderate to Severe Inflammatory Bowel Disease
por: Jukic, Tomislav, et al.
Publicado: (2023)

Infusion reaction to infliximab biosimilar after transitioning from infliximab
por: Kashlan, Reem, et al.
Publicado: (2020)

Infliximab response associates with radiologic findings in bio-naïve Crohn’s disease
por: Yueying, Chen, et al.
Publicado: (2023)

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
por: Ducourau, Emilie, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_1g3r6qbdvlsb08kqj87efv9aca